PDF(Pubmed)
Abstract：
In this paper, we aim to evaluate the efficacy of antidiabetic cardioprotective molecules such as Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) and Glucagon-like Peptide 1 Receptor Agonists (GLP-1 RAs) when used with other glucose-lowering drugs, lipid-lowering, and blood pressure (BP)-lowering drugs in a real-life setting. A retrospective, observational study on 477 patients admitted consecutively in 2019 to the outpatient clinic of a tertiary care unit for Diabetes Mellitus was conducted. Body mass index (BMI), blood pressure (BP) (both systolic and diastolic), and metabolic parameters, as well as A1c hemoglobin, fasting glycaemia and lipid profile, including total cholesterol (C), HDL-C, LDL-C and triglycerides), were evaluated at baseline and two follow-up visits were scheduled (6 months and 12 months) in order to assess the antidiabetic medication efficacy. Both SGLT-2i and GLP-1 RAs were efficient in terms of weight control reflected by BMI; metabolic control suggested by fasting glycaemia and A1c; and the diastolic component of BP control when comparing the data from the 6 and 12-month visits to the baseline, and when comparing the 12-month visit to the 6-month visit. Moreover, when comparing SGLT-2i and GLP-1 RAs with metformin, there are efficacy data for SGLT-2i at baseline in terms of BMI, fasting glycaemia, and HbA1c. In this retrospective study, both classes of cardioprotective molecules, when used in conjunction with other glucose-lowering, antihypertensive, and lipid-lowering medications, appeared to be efficient in a real-life setting for the management of T2DM.
摘要：
在本文中,我们的目的是评估抗糖尿病心脏保护分子的有效性，如钠-葡萄糖协同转运蛋白-2抑制剂（SGLT-2i）和胰高血糖素样肽1受体激动剂（GLP-1RA）与其他降糖药物一起使用时，降脂，和降低血压（BP）的药物在现实生活中。回顾，对2019年在三级护理单位门诊连续收治的477例糖尿病患者进行了观察性研究.身体质量指数(BMI),血压（BP）（收缩压和舒张压），和代谢参数，以及A1c血红蛋白，空腹血糖和血脂，包括总胆固醇（C），HDL-C,LDL-C和甘油三酯），在基线时进行评估，并安排两次随访（6个月和12个月）以评估抗糖尿病药物的疗效。SGLT-2i和GLP-1RAs在BMI反映的体重控制方面均有效；空腹血糖和A1c提示的代谢控制；比较6个月和12个月访视与基线的数据时，血压控制的舒张成分。将12个月的访问与6个月的访问进行比较。此外，当比较SGLT-2i和GLP-1RA与二甲双胍时，SGLT-2i在基线时有BMI方面的疗效数据，空腹血糖，和HbA1c。在这项回顾性研究中,这两类心脏保护分子，当与其他降糖结合使用时，抗高血压药,和降脂药,在现实生活中管理T2DM似乎是有效的。
